Why Is Bliss GVS Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

The Bliss GVS Pharma share price falling by 42 percent from its 52 week high of Rs 158 to the current level of Rs 92 has attracted significant investor attention. This article explains the key reasons behind the Bliss GVS Pharma share price falling trend, provides a full financial analysis, and outlines whether this represents a buying opportunity or a value trap heading into 2026. Track Bliss GVS Pharma live on the Univest Screener.

Click Here to Get Premium Research on Univest

Bliss GVS Pharma Stock Price Snapshot

Parameter	Value
NSE Ticker	BLISSGVS
Sector	Pharma
CMP April 2026	Rs 92
52 Week High	Rs 158
52 Week Low	Rs 82
Decline from 52W High	42 percent

Top Reasons Why Bliss GVS Pharma Share Price Is Falling

Dividend cut announcement surprising investors

Dividend cut announcement surprising investors is the primary driver behind the Bliss GVS Pharma share price falling trend observed over the past several months. Investors tracking Bliss GVS Pharma on the Univest Screener would have noticed the correlation between this factor and the stock’s decline from Rs 158 to Rs 92.

Significant stake sale by institutional investor

Significant stake sale by institutional investor has compounded the pressure on the Bliss GVS Pharma share price, extending the fall beyond what many investors initially expected when the stock first began its correction from the 52 week high of Rs 158. For live FII or DII data, check the Univest Screener.

Broad Market Correction Weighing on Pharma Stocks

The April 2026 US 26 percent reciprocal tariff announcement triggered a broad sell-off across Indian equity markets, with the Pharma sector particularly affected. This macro overhang has contributed significantly to Bliss GVS Pharma share price falling from elevated valuation levels reached at the 52 week high of Rs 158.

Valuation De-Rating After Peak Multiples

Bliss GVS Pharma had reached premium valuation multiples at Rs 158 that were difficult to sustain without consistent earnings beats. When growth expectations moderated, the de-rating process accelerated the Bliss GVS Pharma share price falling to Rs 92. Download the Univest iOS App to track valuation metrics in real time.

FII Selling and Institutional Rebalancing

Foreign institutional investors have been net sellers in several mid and small cap segments of the Indian market since the US tariff shock of April 2026. This institutional selling has amplified the Bliss GVS Pharma share price falling trend beyond what company-specific fundamentals alone would justify.

Financial Analysis: What the Numbers Show

Metric	Current	At 52W High	Commentary
Share Price	Rs 92	Rs 158	Down 42 percent
52 Week Low	Rs 82	Above	Current price above 52W low
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
Net Profit PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing

If you want to track Bliss GVS Pharma’s live financial metrics and peer comparison, check the Univest Screener for real-time data.

Technical Signals for Bliss GVS Pharma Share Price

Bliss GVS Pharma is trading at Rs 92, below its 50 day, 100 day, and 200 day simple moving averages. The stock has formed a pattern of lower highs and lower lows since its 52 week high of Rs 158, confirming a downtrend on charts. Key support is at Rs 82. Key resistance is at Rs 158 where overhead supply will create selling pressure on any recovery attempt. Track Bliss GVS Pharma technical signals on the Univest Android App.

Can Bliss GVS Pharma Share Price Recover?

Despite the current headwinds, genuine recovery catalysts exist for long-term investors. First, if the Pharma sector sees a positive re-rating as macro conditions improve, Bliss GVS Pharma as an established player is likely to benefit. Second, any quarterly earnings result that beats the now reduced expectations could trigger a sharp short-covering rally. Third, a reversal in FII sentiment toward Indian equities would lift Bliss GVS Pharma alongside the broader market.

The contrarian view is that at Rs 92, with the stock down 42 percent from its peak, some of the bad news is already priced in. Valuation has compressed to a more reasonable level. For the latest research on Bliss GVS Pharma, subscribe to Univest Pro for premium stock analysis.

Conclusion

The Bliss GVS Pharma share price falling by 42 percent from Rs 158 to Rs 92 reflects a combination of broad market headwinds, sector-specific pressures, FII selling, earnings deceleration and valuation de-rating. Investors should monitor upcoming quarterly results, changes in FII ownership, and management commentary on the growth recovery trajectory. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

Why is Bliss GVS Pharma share price falling in 2026?

Bliss GVS Pharma share price falling in 2026 is due to dividend cut announcement surprising investors, combined with broader market pressure from the US tariff shock of April 2026 and FII selling. The stock has declined 42 percent from its 52 week high of Rs 158 to the current Rs 92.

What is the 52 week high and low of Bliss GVS Pharma?

The 52 week high of Bliss GVS Pharma is Rs 158 and the 52 week low is Rs 82. The current price of Rs 92 represents a decline of 42 percent from the 52 week high.

Should I buy Bliss GVS Pharma shares at Rs 92?

Whether to buy Bliss GVS Pharma at Rs 92 depends on your investment horizon and risk appetite. The stock has fallen 42 percent from its peak, which improves the risk-reward for patient investors with a 2 to 3 year view. However, near-term volatility may persist. Always consult a SEBI registered financial advisor before investing.

What is the latest news affecting Bliss GVS Pharma stock?

Recent developments affecting Bliss GVS Pharma include the US 26 percent reciprocal tariff announcement triggering FII selling, Q3 FY26 earnings results showing deceleration, and sector-level analyst estimate revisions in the Pharma space. Track the latest news on the Univest Screener.

What are the recovery triggers for Bliss GVS Pharma?

Key recovery triggers for Bliss GVS Pharma include a quarterly earnings beat versus reduced expectations, reversal of FII selling as global macro conditions improve, sector re-rating driven by positive policy developments, and the broader Indian market recovering from the US tariff-related correction.

What are the key downside risks to Bliss GVS Pharma’s stock?

Key risks to any Bliss GVS Pharma recovery thesis include continued earnings estimate downgrades, further FII selling if global risk appetite stays negative, unexpected regulatory changes in the Pharma sector, and a deeper than expected correction in the broader Indian equity market.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026